USA Medical Devices Market Report 2026: FDA Approval, CMS Reimbursement, and GPO/IDN Procurement Intelligence

The US medical devices market is estimated at USD 175–190 billion in 2026 — the world's largest, accounting for approximately 40% of global medical device revenues. The market is characterised by rapid innovation adoption, premium device pricing enabled by private insurance coverage, and GPO (Group Purchasing Organization) and IDN (Integrated Delivery Network) consolidated procurement. Major device companies headquartered in the US include Medtronic, Abbott, Johnson & Johnson MedTech, Stryker, Boston Scientific, Becton Dickinson, Zimmer Biomet, Intuitive Surgical, and Edwards Lifesciences.

FDA medical device regulation operates through three primary pathways: (1) 510(k) Premarket Notification — the most common pathway for Class II devices; requires demonstration of substantial equivalence to a legally marketed predicate device; (2) PMA (Premarket Approval) — required for Class III high-risk devices (e.g., implantable cardiac devices, coronary stents); requires clinical trial evidence of safety and effectiveness; and (3) De Novo Classification — for novel devices with no predicate that pose low-to-moderate risk. The Breakthrough Device Designation accelerates review for devices treating serious conditions with no adequate alternatives. The FDA has also introduced the SaMD (Software as a Medical Device) framework for AI/ML-enabled devices.

CMS (Centers for Medicare & Medicaid Services) reimbursement for medical devices operates through: (1) DRG (Diagnosis-Related Group) bundled hospital payments under Medicare Part A — most inpatient device costs are bundled within the DRG tariff; (2) New Technology Add-On Payments (NTAP) — temporary additional CMS payments for new technologies meeting specific clinical improvement criteria, providing hospitals with additional reimbursement beyond the standard DRG rate for up to three years; (3) CPT codes — procedure-based reimbursement for outpatient and physician-administered procedures under Medicare Part B; and (4) Coverage determinations — NCD (National Coverage Determinations) and LCD (Local Coverage Determinations) issued by CMS and MACs (Medicare Administrative Contractors) establishing coverage criteria.

GPOs (Group Purchasing Organizations) and IDNs (Integrated Delivery Networks) are the dominant procurement channels for US hospital medical devices. The three largest GPOs — Premier, Vizient, and HealthTrust — collectively serve over 4,000 hospitals and command significant pricing leverage. IDNs (HCA Healthcare, CommonSpirit Health, Ascension, Providence, Mayo Clinic system) centralise purchasing across their hospital networks, often bypassing GPO frameworks for strategic device categories. Value analysis committees (VACs) at hospital and IDN level evaluate new devices for formulary inclusion based on clinical evidence, cost-effectiveness, and physician preference. Gaining VA committee approval at major IDN accounts is the most critical commercial access milestone in the US hospital device market.

The fastest-growing US medical device segments are: AI-enabled diagnostics and digital pathology (FDA AI/ML device authorisations growing rapidly); robotic surgery and autonomous surgical systems (Intuitive Surgical da Vinci, Stryker Mako, Medtronic Hugo expanding); continuous glucose monitoring and digital diabetes management (CGM market exceeding USD 10B, driven by Abbott FreeStyle Libre and Dexcom G7); structural heart devices (TAVR, LAAO, MitraClip at significant scale); and neural interfaces and electroceuticals (brain-computer interfaces, neuromodulation for treatment-resistant conditions). Cell and gene therapy manufacturing equipment is a nascent but high-growth category.

The FDA De Novo classification pathway, established under Section 513(f)(2) of the Federal Food, Drug, and Cosmetic Act, provides a route to market for novel, low-to-moderate risk devices that have no legally marketed predicate and therefore cannot use the 510(k) substantial equivalence pathway. Manufacturers submit a De Novo request demonstrating that general controls, or general and special controls, provide reasonable assurance of safety and effectiveness for the intended use, and FDA's CDRH typically targets a 150-day review timeline. A granted De Novo request creates a new device classification — usually Class I or Class II — and, critically for the broader device ecosystem, establishes the device as a predicate that subsequent manufacturers can cite in their own 510(k) submissions, effectively opening a new product category. The pathway has become the primary route for first-of-kind digital health tools, AI/ML-enabled diagnostic software, and novel diagnostic platforms that lack an existing predicate. Companies considering De Novo typically budget for a pre-submission (Q-Sub) meeting with CDRH to align on the clinical and analytical evidence package before filing.

Once a device reaches the US market, FDA's CDRH oversight continues through mandatory Medical Device Reporting (MDR) under 21 CFR Part 803, which requires manufacturers to report deaths and serious injuries within 30 calendar days of becoming aware of an event, and malfunctions that could cause or contribute to death or serious injury if the malfunction were to recur. Manufacturers must file 5-day reports for events that require remedial action to prevent an unreasonable risk of substantial harm to public health, or for other FDA-designated events requiring expedited review. Devices marketed in the US must also carry a Unique Device Identifier (UDI) on their labeling and packaging, with core identifying data submitted to FDA's Global Unique Device Identification Database (GUDID) — a system designed to improve recall precision, adverse event tracking, and supply chain traceability. FDA can also mandate Section 522 postmarket surveillance studies for Class II or Class III devices where failure would have serious health consequences, particularly for implants and life-sustaining devices used in pediatric populations. FDA classifies recalls into Class I (reasonable probability of serious injury or death), Class II (temporary or reversible health consequences), and Class III (unlikely to cause adverse health consequences), and hospital value analysis committees increasingly track a manufacturer's recall and MDR history as part of ongoing vendor performance review.

BioNixus delivers medical device market research in United States: regulator-aware access intelligence, hospital consumption analogues, physician and payer qualitative programmes, and launch evidence under EphMRA and BHBIA governance with GDPR-aligned fieldwork for multinational sponsors. Teams receive decision-ready outputs validated against national policy and institution-level adoption—not desk extrapolation from unrelated regions.

BioNixus supports United States-based medical device companies expanding into GCC and MENA markets with SFDA and MOHAP regulatory intelligence, NUPCO and hospital procurement tracking in Saudi Arabia, UAE insurer and formulary research, physician panels across GCC countries, and comparative United States versus GCC market intelligence. GCC expansion is a distinct service line with its own tender and access calendars—see our GCC pharmaceutical market report for regional context. Launch assumptions should be validated market by market rather than from a single Gulf average.